APA (7th ed.) Citation

Egerer, G., Eisenlohr, K., Gronkowski, M., Burhenne, J., Riedel, K., & Mikus, G. (2010). The NK1 receptor antagonist aprepitant does not alter the pharmacokinetics of high-dose melphalan chemotherapy in patients with multiple myeloma. British journal of clinical pharmacology, 70(6), . https://doi.org/10.1111/j.1365-2125.2010.03792.x

Chicago Style (17th ed.) Citation

Egerer, Gerlinde, Kathrin Eisenlohr, Martina Gronkowski, Jürgen Burhenne, Klaus-Dieter Riedel, and Gerd Mikus. "The NK1 Receptor Antagonist Aprepitant Does Not Alter the Pharmacokinetics of High-dose Melphalan Chemotherapy in Patients with Multiple Myeloma." British Journal of Clinical Pharmacology 70, no. 6 (2010). https://doi.org/10.1111/j.1365-2125.2010.03792.x.

MLA (9th ed.) Citation

Egerer, Gerlinde, et al. "The NK1 Receptor Antagonist Aprepitant Does Not Alter the Pharmacokinetics of High-dose Melphalan Chemotherapy in Patients with Multiple Myeloma." British Journal of Clinical Pharmacology, vol. 70, no. 6, 2010, https://doi.org/10.1111/j.1365-2125.2010.03792.x.